Like in the current case, large cardiac tumours are sometimes seen in infants and can be a cause of sudden cardiac death [1]. The majority are benign and non-invasive, although they may have significant hemodynamic consequences depending on their size and location. The most common type of tumors reported in children and adolescents are rhabdomyomas, and in 50% of the cases are associated with TS complex [1]. Other benign tumours are fibromas, myxomas, and teratomas [2]. Sarcoma is the largest group of primary cardiac malignant neoplasms [3].
For angiofibromas, the usual location is mainly the nasopharynx and head and neck region where it presents with nasal obstruction and nose bleeding. It is most common in adolescent males and thus also referred to as juvenile nasopharyngeal angiofibroma [4]. Histologically, these tumours are well-circumscribed but not encapsulated and are composed of collagenized fibrous stroma with vessels ranging from small slit-like spaces to dilated lumens. No significant cytologic atypia is observed, but multinucleated stromal cells are sometimes seen [5]. The vascular nature is highlighted by angiograms that show a rich blood supply. Angiofibroma is rare to present as cardiac tumour [6].
The clinical features described in the current case show a large cardiac angiofibroma involving the septum and the left ventricular wall. It was associated with pulmonary oedema and vascular congestion. The clinical presentation of a patient with a cardiac tumour is determined more by the tumour’s location than by its histologic type, varying widely from asymptomatic presentations to life-threatening cardiac events by critical obstruction of a valve or outflow tract. Based on their size and position, they may induce arrhythmias and interfere with ventricular compliance [7]. Because of the rapid growth of tumour mass in small-sized cavities, congestive heart failure (CHF) follows and surgical treatment may be lifesaving.
Cardiac tumours often present with CHF manifested by fatigue, oedema, jugular venous distention and ascites. Other symptoms include shortness of breath, syncope and night sweats. Pericardial effusions, venacaval syndrome, pulmonary embolism and restrictive cardiomyopathy may be some of the complications. Because tumours may embolize, they can also lead to seizures, transient ischemic attacks, and cerebrovascular and peripheral-vascular accidents [8].
Echocardiogram is an excellent tool to diagnose the tumour. However, precise information on the tumour histotype is not attainable by echocardiography [9]. A correct therapeutic plan requires an accurate histopathologic diagnosis of the resected mass to rule out the rare case of a malignancy. Computerized tomography (CT) scan, magnetic resonance imaging (MRI) and electrocardiography (ECG) can add to the diagnosis.
In the current case, we lost the child as surgical intervention was being planned. The mode of management varies and cannot be easily simplified because the kind of tumour (whether benign or malignant or infiltrative or localized) dictates therapy. Location and extent of the tumour, as well as symptoms, are clinical variables that direct treatment. Observation is sufficient when the mass is small and does not interfere with vascular hemodynamics. However, when the tumour is causing hemodynamic problems by either obstructing the outflow tract, valve or causing rhythm abnormalities, aggressive management by surgical intervention should be done [8]. In occasional cases, implantation of a pacemaker may be needed if atrioventricular block occurs.
Cardiac angiofibromas are rare paediatric neoplasms and as seen in this report, invariably fatal. There are no series describing the definitive management of these rare cardiac tumours. More insights into their pathogenesis, prevention and treatment are required. There is no definite genetic basis for these and consequently, no notable inheritance patterns.